General
Preferred name
benazepril
Synonyms
BENAZEPRIL HYDROCHLORIDE ()
Benazepril HCl ()
CGS 14824A HCl ()
Lotrel-benazepril hydrochloride / Cibacen ()
Benazepril (hydrochloride) ()
CGS14824A (free base) ()
CGS14824A ()
Benazepril hydrochloride component of lotensin hct ()
Benazepril hydrochloride component of lotrel ()
Lotensin ()
CGS-14824A HCl ()
Benazepril hydrochloride component of cardalis ()
Cibacen ()
Benazepril hydrochloride component of fortekor plus ()
NSC-758920 ()
CGS-14824A ()
C09AA07 ()
Lotrel ()
Benazepril sandoz ()
Cibacen ws ()
Briem ()
Cibacene ()
Forteekor ()
Benazepril-d5 (hydrochloride) ()
P&D ID
PD010141
CAS
86541-75-5
109010-10-8
86541-74-4
1279026-26-4
Tags
available
prodrug
drug
Approved by
FDA
First approval
1991
Drug indication
Hypertension
Cardiovascular disease
Drug Status
vet_approved
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Benazepril (CGS14824A) hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy[1][2].
HALF-LIFE The half life of the prodrug benazepril is 2.7±8.5h[A836]. The half life of the active metabolite benazeprilat is 22.3±9.2h[A836] The accumulation half life of benazepril is 10 to 11 hours[FDA Label][A836].
ROE Benazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function[FDA Label]. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects[FDA Label].
PHARMACODYNAMICS Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by esterases to its active Benazeprilat[A836], is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients[A840,A838,A837]. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals[A840,A836]. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II[FDA Label]. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex[FDA Label].
MOA Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II[FDA Label]. Inhibition of ACE results in decreased plasma angiotensin II[FDA Label]. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion[FDA Label].
INDICATION Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].
METABOLISM Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat[FDA Label]. Benazepril and benazeprilat are conjugated to glucuronic acid prior to urinary excretion[FDA Label].
TOXICITY The most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough[FDA Label,A839]. The most likely symptom of overdosage is severe hypotension[FDA Label].
ABSORPTION Bioavailability of oral dosing is 3% to 4% in horses[A176450]. In humans at least 37% of oral benazepril is absorbed and reaches peak plasma concentration in 0.5 hours to 1 hour[A176453]. Other studies have shown a peak plasma concentration at a median of 1.5 hours[A836].
HALF-LIFE The half life of the prodrug benazepril is 2.7±8.5h[A836].; The half life of the active metabolite benazeprilat is 22.3±9.2h[A836]; The accumulation half life of benazepril is 10 to 11 hours[FDA Label][A836].
TOXICITY The most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough[FDA Label,A839].; ; The most likely symptom of overdosage is severe hypotension[FDA Label].
DESCRIPTION Benazepril (an ACE inhibitor) is administered as an ester is a prodrug, which is metabolized by the liver into its active form . (GtoPdb)
DESCRIPTION Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy[1][2].
DESCRIPTION Angiotensin-converting enzyme (ACE) inhibitor (Tocriscreen Plus)
DESCRIPTION Angiotensin-converting enzyme (ACE) inhibitor (Tocriscreen Total)
DESCRIPTION NSAID, cyclooxygenase (COX-1) inhibitor. Also opener of KIR2.3 (Tocris Bioactive Compound Library)
DESCRIPTION Benazepril is an ACE inhibitor prodrug used to treat hypertension. (Enamine Bioactive Compounds)
DESCRIPTION Benazepril hydrochloride (CGS 14824A HCl) is an angiotensin-converting enzyme (ACE) inhibitor widely used in the therapy of hypertension. Benazepril hydrochloride is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury. (TargetMol Bioactive Compound Library)
DESCRIPTION Benazepril, an angiotensin converting enzyme inhibitor, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. It is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor upon cleavage of its ester group by the liver. (BOC Sciences Bioactive Compounds)
Compound Sets
29
AdooQ Bioactive Compound Library
A10123
BOC Sciences Bioactive Compounds
benazepril-cas-86541-75-5-item-84-78586
Cayman Chemical Bioactives
23804
30978
ChEMBL Approved Drugs
CHEMBL1694
CHEMBL838
ChEMBL Drugs
CHEMBL1694
CHEMBL838
Drug Repurposing Hub
DrugBank
DB00542
DrugBank Approved Drugs
DB00542
DrugCentral
299
DrugCentral Approved Drugs
299
DrugMAP
DMH1M9B
DrugMAP Approved Drugs
DMH1M9B
Enamine Bioactive Compounds
EBC-11216
EU-OPENSCREEN Bioactive Compound Library
EOS101089
Guide to Pharmacology
6374
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL838
Mcule NIBR MoA Box Subset
MCULE-5740870571
MedChem Express Bioactive Compound Library
HY-B0093A
HY-B0093
Natural product-based probes and drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
Benazepril-hydrochloride
benazepril
TargetMol Bioactive Compound Library
T0180
The Spectrum Collection
Tocris Bioactive Compound Library
2578
Tocriscreen Plus
2578
Tocriscreen Total
External IDs
73
Properties
(calculated by RDKit )
Molecular Weight
424.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
9
Ring Count
3
Aromatic Ring Count
2
cLogP
2.57
TPSA
95.94
Fraction CSP3
0.38
Chiral centers
2.0
Largest ring
7.0
QED
0.6
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Target
ACE
Angiotensin-converting Enzyme (ACE)
Apoptosis
Reactive Oxygen Species (ROS)
Akt
RAAS
Reactive Oxygen Species
Primary Target
Angiotensin-Converting Enzyme
MOA
Inhibitor
Angiotensin-I Converting Enzyme (ACE) Inhibitors
angiotensin converting enzyme inhibitor
Member status
member
Indication
hypertension
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antihypertensive
Therapeutic Class
Cardiovascular
Antihypertensive Agents
Pathway
Immunology/Inflammation
Metabolic Enzyme/Protease
NF-κB
PI3K/Akt/mTOR
Endocrinology/Hormones
NF-¦ÊB
Source data